LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)
暂无分享，去创建一个
I. Ray-Coquard | F. Selle | G. Scambia | E. Pujade-Lauraine | B. Schmalfeldt | A. Belau | A. Lortholary | A. Martin | C. Lefeuvre-plesse | M. Gropp-Meier | H. Yoshida | C. Cropet | P. Harter | N. Colombo | G. Bogner | I. Vergote | J. Maenpaa | S. Pignata | A. Leary | E. G. Alia | C. Lefeuvre-Plesse | G. Scambia | E. G. Alía